OSTERHOUT, MARTIN,KALOKO, JOSEPH,HENDERSON, IAN,ZHI, LIN
申请号：
ARP190100359
公开号：
AR114253A1
申请日:
2019.02.13
申请国别(地区):
AR
年份:
2020
代理人:
摘要：
The forms of solid compounds, including compounds of corresponding purity having antagonistic or antagonistic effects on the sulfurized glycerol receptor, and their pharmaceutically acceptable or eutectic and microscopic salts. Improve, delay, or reduce the risk of development or evolution of at least one condition, disease or disorder that shows one or more glucose receptor antagonistic diseases, especially type 1 and type 1 diabetes, insulin resistance, hyperglycemia,Node or node. 1. Claim 1: a crystalline form of (R) - 2 - (4 - (2 - (4 -) - [1,1 '- diphenyl] - 4-il) - 3-oxo-3 - ((2', 4 ', 6' - trimethyl - [1,1 '- diphenyl] - 4-il) amino) benzodiazepine, the characteristic of which is type A. claim 2: the form of claim 1. The type a characteristic is that there are one or more peaks in a powder X-ray diffraction pattern, in which one or more peaks are selected, the peak values are about 4.2 to 4.8 degrees, and the peaks are about 6.7 to 7.1 degrees,The peak value is about 9.0 to 9.4 degrees, the peak value is about 10.8 to 11.2 degrees, the peak value is about 11.1 to 11.5 degrees, the peak value is about 11.7 to 12.1 degrees, and the peak value is about 13.5 to 13.9 degrees, a. The monochromatic radiation measured at ambient temperature is about 21.2 to 21.6 degrees, with a peak value of 23.6 to 24.0 degrees；Formas de compuestos en estado sólido, que incluyen formas enantioméricamente puras de los mismos y sus sales farmacéuticamente aceptables o co-cristalinas y profármacos que tienen actividad antagonista o agonista inversa del receptor de glucagón. También se proveen composiciones farmacéuticas y métodos de tratamiento, prevención, mejoramiento, retraso del inicio o reducción del riesgo de desarrollo o evolución de al menos una condición, enfermedad o trastorno para la cual estén indicados uno o más antagonistas del receptor de glucagón, particularmente la diabetes de Tipo I y Il, la resistencia a la insulina, la hiperglucemia, la cetoacidosis o cetosis. Reivi
